产品
编 号：F345189
分子式：C23H28O12
分子量：496.46
分子式：C23H28O12
分子量：496.46
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 39011-91-1
产品详情
生物活性：
Oxypaeoniflorin, an anti-oxidant, is a monoterpene glycoside compound isolated from Paeoniae species. Oxypaeoniflorin has neuroprotective and anti-inflammatory effects.
体内研究：
Oxypaeoniflorin (OPA; 10-40 mg/kg; intragastrical administration; every day; for 30 days) treatment significantly reduces disruption of cardiac function and improves the indicators of ejection fraction (EF) and fractional shortening (FS). Oxypaeoniflorin significantly reduces the release of myocardial infarction-related factors, such as the creatine kinase (CK-MB), cardiac troponin I (cTnI) and cardiac troponin T (cTnT).Animal Model:C57BL/6 male mice (6-8 weeks of age, 20-25 g) bearing myocardial ischemia/reperfusion (MI/R) injury
Dosage:10 mg/kg, 20 mg/kg, 40 mg/kg
Administration:Intragastrical administration; every day; for 30 days
Result:Significantly reduced disruption of cardiac function and improved the indicators of ejection fraction (EF) and fractional shortening (FS).
体外研究：
Oxypaeoniflorin (OPA; 0.1-10 μM; 8 hours) obviously reversed the hypoxia/reoxygenation (H/R)-induced decrease in cell activity and increase in apoptosis of H9c2 cells. Oxypaeoniflorin inhibits apoptosis by activating the Sirt1 (silent information regulator factor 2 related enzyme 1)/Foxo1(forkhead transcription factor FKHR) signaling pathway in myocardial tissues and H9c2 cells. Oxypaeoniflorin (0-30 μM) attenuates inflammatory effects via regulation of the toll-like receptor (TLR), extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases signaling pathways in LPS-stimulated RAW264.7 cells.
Oxypaeoniflorin, an anti-oxidant, is a monoterpene glycoside compound isolated from Paeoniae species. Oxypaeoniflorin has neuroprotective and anti-inflammatory effects.
体内研究：
Oxypaeoniflorin (OPA; 10-40 mg/kg; intragastrical administration; every day; for 30 days) treatment significantly reduces disruption of cardiac function and improves the indicators of ejection fraction (EF) and fractional shortening (FS). Oxypaeoniflorin significantly reduces the release of myocardial infarction-related factors, such as the creatine kinase (CK-MB), cardiac troponin I (cTnI) and cardiac troponin T (cTnT).Animal Model:C57BL/6 male mice (6-8 weeks of age, 20-25 g) bearing myocardial ischemia/reperfusion (MI/R) injury
Dosage:10 mg/kg, 20 mg/kg, 40 mg/kg
Administration:Intragastrical administration; every day; for 30 days
Result:Significantly reduced disruption of cardiac function and improved the indicators of ejection fraction (EF) and fractional shortening (FS).
体外研究：
Oxypaeoniflorin (OPA; 0.1-10 μM; 8 hours) obviously reversed the hypoxia/reoxygenation (H/R)-induced decrease in cell activity and increase in apoptosis of H9c2 cells. Oxypaeoniflorin inhibits apoptosis by activating the Sirt1 (silent information regulator factor 2 related enzyme 1)/Foxo1(forkhead transcription factor FKHR) signaling pathway in myocardial tissues and H9c2 cells. Oxypaeoniflorin (0-30 μM) attenuates inflammatory effects via regulation of the toll-like receptor (TLR), extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases signaling pathways in LPS-stimulated RAW264.7 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备